Autism Diagnostics Market
Autism Diagnostics Market - Global Industry Trend Analysis 2015 to 2019 and Forecast 2020 - 2028
Autism Diagnostics Market Segmented By type that is Autistic Disorder, Asperger Syndrome and Childhood Disintegrative Disorder with treatment type such as Communication and behavioral therapy, Hyperbaric Oxygen Therapy, Chelation Therapy, Oxytocin Therapy, Drug Therapies
Autism or autism spectrum disorder (ASD) is a mental disability characterized by challenges with social skills including impaired social behavior, speech and communication. The cause of the disorder is uncertain, but some possible factors may include discrepancies in the development of brain function or due to different genetic combinations and environmental influences.
According to the World Health Organization (WHO), the epidemiology study estimated that one in 160 children has an ASD worldwide.
Autism or ASD is the prevailing disabilities. Thus, the early identification, assessment, and diagnosis is the first step toward autism treatment.
Increasing autism patients and rising number of government-sponsored autism awareness programs to promote and provide behavioral health solutions conduction of E-learning program to create awareness in every corner of the world and introduction of reimbursement policies are the factors expected to fuel the autism diagnostics market during the forecast period.
Growing research and development activities to provide effective treatment solutions, rising number of pharmaceutical products for autism treatment, emerging advancement in technology, and pipeline drugs are another key fueling factors for autism diagnostics market. On the other hand, stringent regulations on product approval and lack of awareness expect to hamper the autism diagnostics market growth.
Find Out More about the Report Coverage
|Based on type||
|Based on drug class||
|Based on treatment type||
|Based on the distribution channel||
|Based on the region||
Based on type, the autistic disorder segment holds the major market share in the autism diagnostics market owing to the rising prevalence of ASD among the population. Based on drug class, antipsychotic drug risperidone hold the major market value share owing to the clinical effectiveness of the drug in adults and children.
Based on treatment type, communication and behavioral therapy’s ABA therapy expects to account major revenue share in the autism diagnostics market owing to its ability to provide effective solutions during the therapy based on the behavioral improvement of the patient. Hospital pharmacies hold the major share in the autism diagnostics market due to large patient pool.
North America continues to dominate the global autism diagnostics market owing to the increased number of autism patients, rising awareness among people, increasing investment in healthcare expenditure with the availability of adequate infrastructure and autism diagnostic centers are some of the factors that expected to drive the autism diagnostics market growth in the region. According to the Center for Disease Control & Prevention (CDC), in the U.S. the rate of diagnosis of autism has increased from 16.2% in 2009–2011 to 17.8% in 2015–2017.
Europe is the second-largest region in the autism diagnostics market attributing rising awareness among the population about the ASD, and increased research and development activities in the region. Asia-Pacific is an emerging region owing to rising awareness about early diagnosis in the region.
The Middle East & Africa exhibits the steady growth due to lack of access to healthcare expenditure and lack of awareness among people about the diagnosis but likely to present immense opportunities to the autism diagnostics market during the forecast period.
The key players contributing to the autism diagnostics market are Pfizer, Inc., Novartis AG, Allergan, Merck &Co Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bristol –Myer Squibb, Otsuka Holdings Co., Ltd., Par Sterile Products, LLC, Janssen Pharmaceuticals, Inc., Actavis, Inc., Curemark LLC., Mylan Pharmaceuticals, Asuragen Inc., and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type, drug class, treatment type, and distribution channel.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
The report on the Autism Diagnostics Market covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Historical Actual Market Size, 2015 - 2019
- Market Size & Forecast 2020 to 2030
- Supply & Demand Value Chain
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
- Market Drivers and Restraints
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Regional analysis for the Autism Diagnostics Market includes:
- North America
- Latin America
- East Asia
- South Asia
- Middle East & Africa
Explore Persistence Market Research’s expertise in promulgation of the business !
Report on Autism Diagnostics Market Highlights:
- Shifting industry dynamics
- In-depth market segmentation
- Historical, current, and projected industry size
- Recent industry trends
- Key competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance